ライフサイエンスコーパス: competition binding assay

1 Ki compared with WT RGS2 in a flow cytometry competition binding assay).

2 independently our results with a minicircle competition binding assay.

3 -347, Lys-351, and Lys-414 was verified by a competition binding assay.

4 ed and validated a fluorescence polarization competition binding assay.

5 oluble Lf receptor activity as determined by competition binding assay.

6 d for their capacity to bind protein using a competition binding assay.

7 ity of LY2795050 was measured in radioligand competition binding assays.

8 (hD3) receptor (Ki = 1-5 nM) as measured in competition binding assays.

9 as observed by coprecipitation, overlay, and competition binding assays.

10 higher than their respective Ki values from competition binding assays.

11 sing ELISA, immunohistochemical studies, and competition binding assays.

12 er of potency comparable to that observed in competition binding assays.

13 In competition-binding assays, A-204197 competed with [3H]-

14 ma (PPARgamma), we identified GW9662 using a competition binding assay against the human ligand bindi

15 employed in an automated fluorescence-based competition binding assay, allowing the pKi values of se

16 Evolution of pRNA aptamers was followed by a competition binding assay and nucleotide sequencing, and

17 to GPIIb/IIIa receptors was investigated in competition binding assays and autoradiography using a f

18 Here, we have used competition binding assays and peptide binding assays to

19 ntagonists between the beta-lactamase assay, competition-binding assay, and other direct measurements

20 Competition binding assays at several serotonin receptor

21 Self-exchange competition binding assays between fluorescently labeled

22 The Blitz competition binding assay confirmed target binding of NU

23 In a competition binding assay, DAB4 bound EL4 murine thymic

24 Competition binding assays demonstrate that this binding

25 In vitro competition binding assays demonstrated that 1-4 have a

26 In vitro competition binding assays demonstrated that compounds 9

27 In vitro screening with radioligand competition binding assays demonstrated variable affinit

28 eta oligomer preparations makes conventional competition binding assays difficult to interpret.

29 ated PRP, and 4 nM in solid-phase GPIIb-IIIa competition binding assay (ELISA).

30 ed in vitro in a transactivation assay and a competition binding assay for all RARs.

31 trategy for developing an optimal FRET-based competition binding assay for tyrosine kinases.

32 In competition binding assays FXI/PKA4, FXI/PKA4-Gly326, an

33 [N-methyl]-[(3)H]scopolamine methyl chloride competition binding assay in the presence of GTP.

34 d their binding affinities were evaluated in competition binding assays in HEK 293 cells transfected

35 ide was also shown to be highly selective in competition binding assays in rat brain membranes.

36 to all five human receptors using direct and competition binding assays in solution.

37 A solution competition binding assay, in which a surface immobilize

38 n significantly activate the AHR, and ligand competition binding assays indicate that I3S is a direct

39 Competition binding assays indicate that the binding of

40 Classical competition binding assays measure the binding of a labe

41 onists in [3H]5'-N-ethylcarboxamidoadenosine competition binding assays performed with yeast cell mem

42 Competition binding assays reveal that U2 snRNA (the hig

43 A competition binding assay revealed a dissociation consta

44 Competition binding assays revealed that the anti-SEE an

45 In competition binding assays, SET knockdown increased high

46 Competition binding assays show minimal dissociation of

47 Competition binding assays showed 11-25 and 27-31 bound

48 combined with cross-linking experiments and competition-binding assays showed that the fully disorde

49 Furthermore, competition binding assays suggest that Q509L decreases

50 A competition binding assay suggested a direct interaction

51 The pharmacological profile from competition binding assays suggests that the ligands may

52 analysis and/or by [125I]alpha-bungarotoxin competition binding assays the interactions of acetylcho

53 In competition binding assays, the affinity of agonists is

54 ing affinity but similar to those shown in a competition binding assay to displace radioiodinated ana

55 In equilibrium competition binding assays to membranes from Sf9 cells i

56 We demonstrate the use of a DNA minicircle competition binding assay, together with DNA cyclization

57 nitor C protein-oligonucleotide binding in a competition binding assay under equilibrium conditions.

58 In a competition binding assay using the p85 PI 3-kinase C-te

59 ng was assessed in mobility shift assays and competition binding assays using cisplatin-damaged DNA.

60 Binding affinity was measured via competition binding assays using hB1R-expressing Chinese

61 BIAcore analysis and competition binding assays using LOX human malignant mel

62 s and pharmacokinetic studies in mice and in competition binding assays using recombinant, soluble Fc

63 Competition binding assays using stably transfected L293

64 68, and (nat)Ga-JMV5132 were determined in a competition-binding assay using GRPR-overexpressing PC-3

65 Using a competition binding assay, we have established that Klen

66 Using a competition binding assay, we show that the affinity of

67 Using competition binding assays, we find that short C-termina

68 Using competition binding assays, we further characterized thi

69 Using GW2331 as a radioligand in competition binding assays, we show that certain mono- a

70 etic resonance spectroscopy and protein-drug competition binding assays were employed to define the g

71 Competition binding assays were employed to examine the

72 A BRET-based competition binding assay with 4 was also established an

73 e (Mr approximately 250-500 Da) ligands in a competition binding assay with cyclosporin A (CsA).

74 Competition binding assays with [(3)H]MRS2279 and P2Y1-R

75 Competition binding assays with b12 also showed that b12

76 tudy ligand-protein interactions by coupling competition binding assays with mass spectrometry-based

77 ant (C1)4 and (C2)4 homotetramers along with competition binding assays with poly(A) and poly(C) indi

78 Selected probes were tested in competition binding assays with unlabeled competitors in